




Characterization the Role of Telomeric RNA (TERRA) in Telomeric DNA Double-Strand Break 




Taghreed Mohammed Alturki 
Graduate Degree Program in Cell and Molecular Biology 
 
 
In partial fulfillment of the requirements 
For the Degree of Doctor of Philosophy 
Colorado State University 













Copyright by Taghreed Mohammed Alturki 2019 






Telomeres are specialized nucleoprotein complexes that protect natural chromosomal 
termini from degradation and prevent their detection as of DNA damage.  Therefore, telomeres 
play critical roles in maintaining genomic stability. Telomeres are composed of tandem arrays of 
conserved repetitive sequences (TTAGGG in vertebrates), bound by a suite of proteins collectively 
termed "shelterin". Shelterin proteins are essential for telomere length regulation and end-capping 
structure/function. Due to their repetitive nature and together with telomeres possessing an 
abundance of heterochromatic marks, telomeres have long been regarded as silenced, non-
transcribed features of the genome.  
The relatively recent discovery of telomeric RNA (TElomere Repeat- containing RNA; 
TERRA) opened many new avenues of investigation. TERRA is a long, noncoding RNA (lncRNA) 
that serves a structural role at telomeres, as well as function in regulation of telomere length and 
telomerase activity, the specialized reverse transcriptase capable of elongating telomeres de novo. 
Further, TERRA participates in telomeric recombination in tumors that maintain telomere length 
in a telomerase independent fashion via the Alternative Lengthening of Telomeres (ALT) pathway. 
Emerging evidence also supports telomeric “DNA- TERRA hybrids” as indispensable for end 
protection and capping function; e.g., RNA interference mediated depletion of TERRA induced 
telomeric DNA damage responses (DDRs) and aberrations. Thus, TERRA participates in 
facilitating telomeric recombination and in preventing inappropriate telomeric DNA damage 
responses. We hypothesized that TERRA plays a critical role in the repair of telomeric DNA 
damage. To address the intriguing possibility that TERRA plays a role in the telomeric DNA 
damage response, we evaluated the colocalization of TERRA and γ-H2AX, a well-accepted 
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marker of double-strand breaks (DSBs), at broken telomeres in human Osteosarcoma U2OS-ALT 
cells in different phases of the cell cycle.  
To test our hypothesis, we generated U2OS-ALT cells that stably expressed FUCCI green 
fluorescent signals to label cells in G2 phase. Telomeric DSBs were then induced in FUCCI-U2OS 
cells utilizing the ENT endonuclease fused to Telomere Repeat Factor 1 TRF1 (ENT-TRF1), and 
validated via colocalization of telomeres with γ-H2AX-FLAG. Forty-eight hours following 
transfection, FUCCI-U2OS cells were also treated with EdU to label cells in S phase. Cells 
negative for both FUCCI and EdU identified cells in G1 phase. Using this powerful strategy to 
distinguish cells in G1, S and G2 phases of the cell cycle, we showed that FUCCI-U2OS cells 
accumulate in G2 phase following transient transfection with ENT-TRF1. We validated that 
expression of ENT-TRF1 generates telomeric DSBs in U2OS-ALT cells through detection of 
telomere- γ-H2AX-FLAG colocalization events. Importantly, our data revealed that telomeric 
DSB induction triggers enrichment of TERRA in G2 phase. Taken together, these observations 
suggested that TERRA is increased in cells transfected with ENT-TRF1; i.e., in U2OS cells 
harboring telomere-specific DSBs.  
TERRA recruitment to telomeric DSB damage sites in G2 was validated by assessing co-
localization between TERRA and ENT (FLAG). Similarly, TERRA recruitment to telomeric DSBs 
in G1/S was also evaluated.  Futhermore, non-denaturing Telomere DNA FISH was employed to 
visualize G-rich and C-rich single-stranded (ss)telomeric DNA. Treatment of U2OS ENT 
transfected cells with Rnase A and Rnase H to remove TERRA, uncovered elevated levels of 
resected 5’ C-rich (ss)telomeric DNA (complementary TERRA sequence), suggesting a potential 
role for TERRA in protecting resected telomeric DNA prior to cells entering G2 phase where 
Homologous Recombination (HR)-mediated elongation/repair would be possible.  
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Consistent with published reports, telomeric DSBs were also significantly induced in cells 
transfected with TRF1-only (positive control). However, although TERRA co-localized with 
FLAG/broken telomeres, resected (ss)telomeric DNA was not detected upon removal of TERRA. 
Therefore, our results further support induction of telomeric DSBs with overexpression of TRF1, 
and additionally indicate that they are repaired via a different pathway than those induced by ENT, 
potentially alternative End Joining (alt-EJ), as previously proposed.   
In conclusion, our work revealed for the first time that the telomeric RNA TERRA, is 
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Telomere structure and function  
Telomere structure 
Telomeres are specialized nucleoprotein structures at the ends of linear chromosomes, 
composed of tandem arrays of repetitive sequence (5’-TTAGGG-3’ in mammalian cells) [2] [3], 
and associated with a variety of proteins, six of which are collectively called shelterin [4]. While 
telomere-specific proteins Telomere Repeat Factor 1 (TRF1) and Telomere Repeat Factor 2 (TRF2) 
bind double-stranded telomeric DNA as homodimers [5-7], Protection of Telomeres 1 (POT 1) 
binds only single-stranded telomeric G-rich DNA [8]. Repressor-activator protein 1 (RAP1) binds 
telomeres via its interaction with TRF2 [9]. TRF1 and TRF2/RAP1 are linked through TRF1-
Interacting Nuclear protein 2 (TIN2) [10]. TIN2- and POT1-organizing protein (TPP1) connects 
POT1 and TIN2 proteins [11]. A recent study discovered an additional regulator of telomere length, 
the telomeric zinc finger-associated protein (TZAP), which binds telomeric G-rich strands of long 
telomeres and trims them [12].  Telomeres can range in size from ~1Kbp-15Kbp [13]. 
Structural studies using Electron Micrographs in human cells revealed that chromosomal 
termini form large telomeric loops (T-loop), where the top single-strand (3’ G rich overhang) loops 
back and hybridizes to the telomeric double-stranded DNA. The invading double-stranded 
telomeric DNA with G-rich single strand also creates a smaller Displacement loop (D-loop; Figure 
1.1) [14-16]. In addition to T-loops, Nuclear Magnetic Resonance Spectroscopy (NMR) and X-
ray crystallography studies support G-quadruplexes as a secondary telomeric structure in human 




Due to the repetitive nature of telomeres, they were long regarded as silent heterochromatin. 
However, the discovery of long non-coding (lnc)RNA Telomeric Repeat-containing RNAs 
(TERRA 5’-UUAGGG-3’) recently negated this notion [20-22]. It has also been observed that 
TERRA can directly bind telomeres via the C-rich strand, forming TeloDNA:TERRA hybrids, or 
indirectly by way of association with shelterin proteins [23, 24]. There is also a fraction of TERRA 
not bound to telomeres, or free TERRA [25] .  
 
 
Figure 1.1: A schematic of mammalian telomere structure. 
 
Homodimers of TRF1 and TRF2 bind directly to double-stranded telomeric DNA, while POT1 binds to single-
stranded G-rich telomeric overhangs. Shelterin proteins interact with the telomere sequences indirectly via protein-
protein interactions (lower left). The 3’ G-rich overhang invades the telomeric duplex, forming a t-loop and D- loop 
(Upper right) [26].  
 
Telomere Function 
Telomeres serve to solve two main problems resulting from the linearity of eukaryotic 
chromosomes; the challenge to replicate the very end of linear DNA molecules (the end replication 
problem) [27], and the threat of activating a DNA Damage Response (DDR) upon misidentifying 
the end of chromosomes as a double-strand break (DSB; the end protection problem) [26, 28]. 
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The End Replication Problem 
In order to synthesize a new DNA strand from the parental strands, RNA primase binds the 
3’ end of the parental leading strand to provide a primer (short RNA sequence) with a free 3’ OH 
group. DNA polymerase III requires that free 3’ OH group on the primer to add new deoxyribose 
nucleotides dNTPs spontaneously in the 5’ to 3’ direction toward the replication fork. Due to the 
nature of the antiparallel double stranded DNA, RNA primase binds various sites along the 
parental lagging strand to provide small pieces of primers with 3’ OH groups so DNA polymerase 
can add new dNTPs in the 3’ direction in between the primers. Eventually, the RNA primers are 
removed and replaced with DNA sequences using DNA polymerase I [29, 30].   
The DNA end -replication problem arises at the very end of telomeres after removing the 
5’ distal primer on the lagging-strand, which cannot be replaced with DNA sequence due to the 
lack of 3’OH group. Consequently, with every cell division telomere length progressively shortens 
by 30-200 base pairs [26, 31, 32]. Telomere shortening has been strongly associated with aging 
and age-related diseases [33]. Although the end replication problem is unavoidable, telomere 
shortening can be offset by telomerase, a specialized DNA polymerase capable of adding telomere 
sequence de novo onto newly replicated ends. However, telomerase is only sufficient to maintain 
telomere length in stem, germ-line, and cancer cells [34, 35]. 
Telomerase  
The discovery of telomerase in Tetrahymena contributed to better understanding of how 
cells maintain the length of telomeres [36]. Structurally, telomerase is a ribonucleotide enzyme 
comprised of three main subunits. First, the catalytic Telomere Reverse Transcriptase (TERT) 
protein encoded by the TERT gene in humans (hTERT). The second subunit is a long non-coding 
RNA called Telomerase RNA Component (TERC) with a sequence complementary to the G rich 
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telomeric strand (3’-AAUCCC-5’). A collection of proteins make up the third subunit, which play 
a role in telomerase stabilization and sequestration [37].  
Telomerase is well appreciated for its role in providing a template for DNA replication in 
order to maintain the length of telomeres [35, 38].  The recruitment of telomerase to telomeres is 
regulated by telomere length and cell cycle phase. Studies have demonstrated that telomerase is 
preferentially recruited to short telomeres in S phase/during replication when the T-loop is 
unfolded.  Additionally, some shelterin proteins participate in regulating telomerase-telomere 
binding. It has been proposed that long telomeres, which would be bound by more TRF1, would 
also recruit more PIN2 TRF1 Interacting Telomerase Inhibitor (PINX1), thereby blocking access 
of telomerase to the 3’end [39, 40].  
On the other hand, the POT1-TPP1 complex facilitates telomerase-telomere localization 
via its telomerase N-terminus (TEN) domain [41, 42]. In germ-line, stem, and cancer cells, high 
levels of telomerase activity ensure telomere length maintenance. Conversely, normal human cells 
lack sufficient telomerase activity to restore lost nucleosides, and thereby limit the number of cell 
divisions (Hayflick number) [43]. Critical telomere shortening in normal human cells triggers 
replicative senescence or apoptosis, preventing further cell division and providing an effective 
tumor suppressor mechanism [44]. 
The End-Protection Problem 
Functional telomeres cap linear chromosomes; they prevent recognition of natural DNA 
ends as DSBs by repair enzymes such as Ataxia-Telangiectasia-Mutated (ATM) and Ataxia 
Telangiectasia and Rad3- related (ATR) kinases, and Poly (ADP-Ribose) Polymerase 1 (PARP1), 
and so avoid triggering of inappropriate DDRs.  Functional telomeres block DSB repair pathways 
classical Nonhomologous End Joining (c-NHEJ), alternative alt-EJ, and Homologous 
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Recombination (HR), and limit telomere hyper-resection [26, 45, 46]. Each repair pathway will be 
discussed in greater detail below. 
Loss of telomere sequence or structure (e.g., the T-loop), and/or disrupting the shelterin 
complex results in compromised end-capping and inappropriate engagement of DSB repair 
pathways at telomeres. Telomere dysfunction-induced foci (TIF) are indicative of loss of end-
protection, potential consequences of which include end-fusions between chromosomes and/or 
sister chromatids (setting up Breakage-Fusion-Bridges cycles) and induction of genomic 
instability [47, 48].  
Telomeres, immortality, and cancer 
Normal cells in long-lived mammalian species with  short telomeres can stop dividing and 
remain in state of replicative senescence for years as a strategy to suppress carcinogenesis [44]. 
Human fibroblasts can escape the replicative senescence barrier and divide again by inactivating 
tumor suppressor genes such as p16INKa, Rb or p53. Some of the cells that emerge also pass a 
second barrier known as crisis [49], which involves loss of functional telomeres. Chromosomal 
fusions and rearrangements, genomic instability, telomerase activity upregulation, and ultimately 
cancer result [50, 51]. Ectopic expression of telomerase in telomerase silent human cell lines 
causes cells to bypass senescence and crisis, leading to immortalization - one of the hallmarks of 
cancer [52, 53].  
Telomere Length Maintenance via Telomerase reactivation or Alternative Lengthening of 
Telomere pathway (ALT). 
Telomerase positive tumors 
The Telomerase Repeat Amplification Protocol (TRAP) assay demonstrated that 85-90% 
of human tumors rely on reactivation of  telomerase to maintain telomere length and enable 
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replicative immortality [50, 54]. Upregulation of telomerase is attributed to mutations in the 
hTERT promoter in some types of cancers; e.g., 80-90% of gliomas, 70% of melanoma, and 60% 
of bladder cancers [55, 56].  Two single base-pair mutations located -146 and -124 upstream from 
the start codon of hTERT gene (c.−146C>T and c.−124C>T) have been reported to generate a new 
binding site for ETS transcription factor leading to upregulation of hTERT protein [57-59].  
In addition to the ETS transcription factor, chromatin marked with histone H3 Lysine4 di-
methylation H3K4me2/3 provides a site of GABPA/B1 transcription factors. GABPA/B1 
transcription factors were also involved in hTERT upregulation. Intriguingly, H3K4me2/3 was 
absent from wild-type hTERT promoter and replaced with Histone H3 Lysin27 trimethylation 
H3K27me3, the epigenetic signature of gene silencing indicating that mutant promoter is also 
accountable for the epigenetic changes. However, it is still unknown if the GABPA/B1 alone is 
sufficient to activate telomerase transcription, or if the transcription requires ETS and GABPA/B 
[60, 61]. 
On the contrary, other types of cancer such as breast, ovarian, and gastric cancers have very 
low frequencies of hTERT promotor mutation; these cancers do not require promoter mutations to 
reactivate telomerase [62].  
Alternative Lengthening of Telomere pathway (ALT) Tumors 
The remaining ~10% of tumors utilize an Alternative Lengthening of Telomeres (ALT) 
pathway to maintain telomere length [63-66]. These tumors represent aggressive cancer types; e.g., 
50% of osteosarcomas, 30% of soft tissue sarcomas, and 25% of primary brain tumors. Clinically, 
ALT tumors are less likely to metastasize, but a smaller fraction of patients survive compared to 
telomerase positive tumors [67, 68].  ALT cells can be identified by the presence of various 
characteristic hallmarks. In addition to telomerase activity being low or absent, telomere length is 
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very heterogeneous in ALT cells, as shown by Terminal Restriction Fragment (TRF) Southern 
blots [63].  ALT cells are also associated with discrete types of Promyelocytic leukemia (PML) 
nuclear bodies called ALT-associated PML bodies.  ALT-associated PML bodies are found in the 
nucleus, are ~0.1–1.0 μm in diameter, and contain telomeric DNA, TRF1, TRF2, and DNA repair 
proteins [69].  Compared to telomerase positive cells, a significantly elevated number of telomere-
sister chromatid exchange (T-SCE) events has been reported in ALT cells [64]. SCE is a common 
template-switching mechanism used by cells to resolve replication stress; SCE within telomeres 
can be detected by Chromosome Orientation Fluorescence In Situ Hybridization (CO-FISH) assay 
[70-72].  
ALT cells are also associated with telomeric C-circles, which were first detected in 
osteosarcoma patients; C-circles are not present in telomerase positive cells, so they are specific 
for ALT tumors [73, 74]. A recent study showed that mutated α-thalassemia/mental retardation 
syndrome X-linked (ATRX) and death domain-associated protein (DAXX), which are associated 
with decompacted telomeric chromatin, are also hallmarks of ALT [75-78]. One possible 
explanation is that functional ATRX and its physical partner DAXX facilitate histone variant 
H3K9me3 deposition. Therefore, altered ATRX/DAXX hinders H3K9me3 incorporation, which 
can change the chromatin state [79, 80].  One potential consequence, increased transcription 
through telomeres, would result in elevated levels of telomeric RNA,TERRA when compared to 
telomerase positive tumors with functional ATRX/DAXX and compact chromatin [81-83]. 
ALT-mediated telomeric DNA synthesis by Break-Induced Replication (BIR) 
Gaining mechanistic understanding of how cells maintain telomere length independently 
of telomerase activity, can lead to novel strategies for ALT cancer therapy.  Over the last several 
decades, significant progress has been made in understanding the molecular mechanism of ALT 
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[84-86].  Appreciation for an ALT mechanism in human cancer and normal mouse cells was first 
gained using fluorescently tagged DNA sequences inserted into telomeres. FISH analysis showed 
that the passage doubling number of ALT cultures is positively correlated with the number of 
tagged telomeres. For instance, in human ALT cells with passage number 23, the fluorescent 
tagged DNA was found only on three telomeres. This cell culture was subcultured 40 times, the 
fluorescent tagged DNA was then detected on 5 telomeres indicating that telomeres can exchange 
their own sequences.  However, the same observation was not detected when tagged DNA was 
inserted at centromeres, nor in telomerase-dependent cells [87-89]. This unique telomeric 
recombination event had been previously described in telomerase-independent saccharomyces 
cerevisiae yeast when Dunn et al [90] introduced a short linearized DNA fragment lacking 
telomere sequence. They found that short DNA fragments became longer and more stable by 
gaining yeast telomeric DNA sequence in the presence of RAD52.   
Walmsley et al  [91] also demonstrated that telomere maintenance can be accomplished by 
using another telomere as a template. In addition to the role of recombination in maintaining 
telomeres, investigation focused on the role of telomeric recombination in telomeric DSBs in S. 
cerevisiae. Bosco and Haber [92] used HO endonuclease to cut off telomeres on specific 
chromosomes, generating a one ended-DSB. They reported that the broken chromosome was 
repaired using either the homologous telomere sequence on the same chromosome in haploid 
genome, or the non-sister telomere in diploid genome only in the presence of RAD52, which is 
necessary for recombination. Furthermore, cutting telomeres using HO in S. cerevisiae showed 
that BIR requires polymerase Delta, pol δ, and its subunit pol32, enhanced by Pif1-PCNA complex, 
to primase DNA synthesis within the migrating D-loop [93, 94]. Collectively, these results suggest 
a model for the Break-Induced Replication (BIR) repair pathway. BIR is the recombination-
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dependent DNA replication pathway in which RAD52 binds resected 3’ ends and promotes the 
homologous telomeric double-stranded DNA invasion and formation of a D-loop, a critical step 
during BIR followed by DNA synthesis (Figure 1.2) [95].  
 
Figure 1.2: A model of telomere repair, via BIR pathway, in the absence of telomerase enzyme 
in Saccharomyces cerevisiae.  
 
One ended-double strand break generated after inducing a site-specific HO. Rad52 and Rad59 are required for 
successful strand annealing and D-loop formation. The Pif1-PCNA complex primase DNA synthesis within the 
migrating D-loop [95].   
 
A similar cleavage strategy has been used in ALT Osteosarcoma- U2OS mammalian cells 
by employing endonuclease protein FOKI fused to telomere shelterin protein TRF1 (FOKI -TRF1) 
[96].  Inducing telomeric-specific DSBs gave a direct answer as to whether the BIR pathway uses 
another homologous telomere as a template to repair the damage. This intriguing study used BrdU 
incorporation to measure telomeric DNA synthesis in cycling cells. Following induction of 
targeted telomeric DSBs, the length of nascent telomeres ranged between 5 - 70 kb in the presence 
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or absence of RAD51, suggesting two different BIR pathways; one being RAD51-dependent and 
one RAD51-independent. In the presence of RAD51, recombination between telomeres of 
different chromosomes was detected and contributed to DNA synthesis. In RAD51 deficient cells, 
BIR relied on the POLD3 subunit of human pol δ to synthesize DNA without detecting any 
recombination activity. Other supporting evidence includes telomerase positive cells treated with 
BIBR1532,telomerase inhibitor; over a six week times period, sustained telomeric DSBs showed 
longer telomeres compared to cells that were not treated with BIBR1532 [97]. 
 
 
Figure 1.3: A model of telomere repair, via BIR pathway, in the absence of telomerase enzyme 
in ALT cancer cells.  
 
A one ended-DSB generated after expressing telomere-specific endonuclease FokI is depicted above. Homology 
search in presence of Rad51 was detected between telomeres on different chromosomes.  In absence of Rad51, 




In addition to the role of RAD51 in BIR, a recent study revealed that the efficiency of BIR 
was drastically reduced in RAD52-KO G2 U2OS (ALT) clones, but not in RAD52-KO G2 
telomerase positive clones [98].  In agreement with Dilley et al [96], they showed that BIR 
efficiency was not impaired in RAD51-KO G2 ALT clones in the presence of POLD3, confirming 
that RAD51-independent BIR pathway is mediated by pol δ in ALT.  
Overall, the exploitation of developed experimental approaches has allowed for improved 
understanding of BIR as a mechanism of ALT in different organisms and different cell stages, as 
well as the roles of recombination and replication proteins in maintenance of telomere length [98]. 
Chromatin landscape changes and increased Telo:TERRA hybrids mediate telomere 
elongation in ALT cells 
While endonuclease FOKI-induced telomeric DSBs has refined our understanding of how 
recombination mediated telomere synthesis occurs in ALT cells, the endogenous events that 
provoke ALT remain unclear. Most studies concede that modification of telomere chromatin 
conformation may be the main factor that initiates ALT. Specifically, it has been reported that 
inhibition of the histone chaperon Anti-Silencing Factor1 (ASF1) in  telomerase positive cells 
represses expression of endogenous hTERT and promotes telomeric recombination [99]. 
Additionally, the telomere chromatin remodeler (ATRX) and its partner (DAXX) facilitate 
assembly of H3 histone variant H3.3 and H3 lysine 9 trimethylation (H3K9me3) to establish 
heterochromatin marks at telomeres. Mutation of the ATRX-DAXX complex, a hallmark of ALT, 
results in relaxed telomeric chromatin, facilitating access of BIR proteins to achieve telomere 
maintenance [79, 80]. Decompaction of telomeric DNA due to ATRX mutation has been 
associated with low levels of H3K9me3 and elevated levels of TERRA in ALT cells. In support 
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of such a role, RNAi KO of ATRX in telomerase positive cancer cells displays increased levels of 
TERRA [81-83].  
The next question examined was whether ALT cells possess elevated levels of TERRA 
compared to telomerase positive cells.  Fragmented DNA extracted from U2OS cells was subjected 
to DNA ImmunoPrecipitation (DIP) to detect Telo-RNA hybrids. This was done using S9.6 
antibody to compare it to amount of TERRA in HeLa cells as a model of telomerase positive cells. 
The results showed that in contrast to telomerase positive cells, a significant increase of 
Telo:TERRA hybrids and elevated level of C-circles were observed. Interestingly, removing 
hybridized TERRA by overexpression of endogenous RnaseH1 in ALT cells resulted in telomere 
lengthening.  These results support the contribution of elevated levels of Telo:TERRA hybrids in 
ALT-mediated BIR to maintain the length of telomeres [100]. TERRA has also been implicated in 
telomere mobility, in both ALT and telomerase positive cells, and to facilitate physical telomere-
telomere interaction required for recombination [101, 102]. 
Increasing evidence suggests that Telo:TERRA hybrids are engaged in recombination- 
mediated telomere elongation in yeast. Depleted telomerase recruitment factor (Coiled-Coil 
protein Quantitatively ccq1) in Schizosaccharomyces Pombe cells have shown to have elevated 
levels of TERRA and Telo:TERRA hybrids associated with efficient telomeres recombination. 
[102]. On the other hand, repression of Telo:TERRA hybrids by way of overexpression RnaseH1 
led to a sever growth crisis [102]. It has also been suggested that in S. cerevisiae, Telo:TERRA 
hybrids could contribute to stabilizing the D-loop to promote telomere recombination [103, 104]. 
Together, these observations suggest that Telo:TERRA hybrids can serve as substrates for 
recombination- mediated telomere elongation. 
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Long Non-coding RNAs 
Over the past decade,  molecular biology studies have discovered that  98% of the genome 
is transcribed into non-coding RNAs [105, 106]. Long non-coding (lnc)RNAs are a type of non-
coding RNAs that interact with different proteins to achieve cellular functions [20, 21, 82, 107]. 
The telomeric lncRNA TERRA is important for telomere structure and function.  
Long non-coding Telomeric repeat-containing RNA: TERRA 
TERRA Biogenesis 
Telomeres were long thought to be transcriptionally silent due to their hypermethylated, 
inhibitive chromatin status [21, 107]. Discovery of the long non coding RNA, TERRA, challenged 
this historic and central tenet of telomere biology [20]. It is now known that TERRA transcription, 
driven by RNA polymerase II (RNAPII), can progress several kilobases through the C-rich 
telomeric strand before releasing the final product (Figure 1.4) [108]. Work In U2OS has shown 
that cohesion, and CCCTC-Binding Factor (CTCF) transcription factor work in concert to 
positively regulate TERRA transcription via their roles in RNA Pol II recruitment [109].   
TERRA has been detected in yeast, mouse, human, zebrafish and plants.  [20, 108, 110, 
111].  Human TERRA is very heterogeneous in length, ranging from ~100bp to 9kb of 5’-
UUAGGG-3’ repeats, suggesting different promoter location sites [20, 108]. In support of this 
view, two sets of TERRA promoters within subtelomeres have been characterized. Detection of 
pSer2 and pSer5 (active form of RNA pol lI) binding sites 1Kb from telomere repeats helped 
identify the first set of TERRA subtelomeric promoters. Notably, these promoters are rich in 
dinucleotide CpG islands upstream of the Transcription Start Site (TSS) [109, 112]. RNA-seq 
approaches in HeLa cells revealed a second set of TERRA promoters located 5-10kb from 
telomeres on 10 different chromosomes [113]. 
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Utilizing CRISPR-Cas9 genome editing to remove 8 kbp on the long arm subtelomere of 
chromosome number 20 in human U2OS cells resulted in significant TERRA depletion, indicating 
that a significant amount of TERRA is transcribed from one chromosome [114]. Similarly, the 
majority of mouse TERRA has been shown to be transcribed from chromosome number 18 [115]. 
Other recent work demonstrates that human TERRA is transcribed from many chromosomes [116] 
TERRA Structure 
Structurally, while the 5’ end of TERRA is capped with 7-methylguanosin (m7G), a 
specific fraction of the 3’ end of total TERRA is polyadenylated, leaving the remaining 3’ ends 
nonpolyadenylated. Polyadenylation is an important factor in determining the half-life and the 
binding status of TERRA. That is, nonPoly A TERRA has a shorter half-life (3h), but localizes to 
telomere tracks forming Telo:TERRA hybrids (bound TERRA). This is in contrast to poly A 
TERRA, which has a longer half-life (8h), but does not associate with telomeres (free or unbound 
TERRA) [25].  
TERRA Decay 
Telo:TERRA hybrids can be advantageous to ALT cells; however, replication stress 
associated with Telo:TERRA hybrids in ALT and telomerase positive cells has been reported.  
Thus, regulation of TERRA levels and binding activities are important for maintaining stability.  
For instance, in addition to RnaseH1, HeLa cells deficient in UP-Frameshift 1 (UPF1), a 
member of the nonsense-mediated mRNA decay pathway, display elevated levels of Telo:TERRA 
hybrids with no associated increase in TERRA transcription, revealing UPF1 as a negative 
regulator of bound TERRA [20]. A recent study identified TRF1, which facilitates replication 
through telomeres, as another negative regulator of bound TERRA [117]. In contrast to TRF1, 
depletion of TRF2 results in upregulation of TERRA transcription [113].  The NONO/SFPQ 
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heterodimer complex has also been proposed as a suppressor of undesirable levels of Telo:TERRA 





Figure 1.4: A model of TERRA transcription through telomere.  
 
RNA Pol II drives transcription of UUAGGG long non coding telomeric RNA through telomeres [1]  
 
TERRA dynamics through the cell cycle in Telomerase positive and ALT cells 
Shortly after the discovery of TERRA, intense investigation into TERRA transcription and 
localization commenced, in both telomerase positive and ALT cells; reviewed in [119]. Porro et. 
al. evaluated TERRA levels from four different telomeres in synchronized HeLa (telomerase 
positive) G1/S cells, compared to TERRA levels from the same four telomeres in cells in S and 
G2/M phases. Results revealed that TERRA transcription is cell cycle dependent, with levels 
peaking in G1/S and decreasing through the cell cycle until cells reenter G1 and levels start to 
increase again [25].  
Many reports gave insights into the necessity of having regulated levels of TERRA through 
the cell cycle in telomerase positive cells. Flynn et al observed that replication protein A (RPA) 
was able and sufficient to displace the shelterin POT1-TPP1 complex from telomeric ssDNA. 
However, the reverse experiment revealed that the POT1-TPP1 complex did not replace RPA 
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[120].  Knowing that RPA plays a role in ATR-mediated telomeric DNA repair activation, the 
investigation of how RPA released from telomeres was needed.   
Biochemical studies showed that RPA is displaced from telomeric ssDNA when 
heterogeneous nuclear ribonucleoproteins (hnRNPs) bind telomeric ssDNA, which occurs only in 
the absence or low concentration of TERRA. Further investigation showed that elevated levels of 
TERRA bind and sequester hnRNPs, allowing RPA to displace POT1-TPP1 complex from ssDNA 
[120].  Taken together, published results provide an attractive model explaining why TERRA 
levels are tightly regulated through the cell cycle in telomerase positive cells (Figure 1.5).  
In this model elevated levels of TERRA in G1 and G1/S sequester hnRNPs, allowing RPA 
to antagonize POT1-TPP1 complex binding to telomeres. Bound RPA is critical for DNA 
replication during S phase. Reduced levels of TERRA in S/G2 are insufficient to sequester hnRNPs, 
thereby facilitating RPA binding. An increase in TERRA during M/G1 leads to sequestering 
hnRNPs, again allowing the POT1-TPP1 complex to bind, cap telomeres and prevent the activation 
of ATR  [119].   
In conclusion, regulated levels of TERRA through the cell cycle in telomerase positive 
cells play an important role in telomere replication and end-capping [121]. In contrast, in ALT 
U2OS cells synchronized in S phase (via thymidine block), RNA FISH detected elevated levels of 
TERRA in S phase compared to what had been observed in telomerase positive HeLa cells. 
Furthermore, RNA dot blots of U2OS cells treated with a CDK1 inhibitor to enrich for cells in G2, 
did not show any reduction of TERRA levels as cells released from S into G2 [81]. These results 
indicate that in contrast to telomerase positive cells, TERRA levels in ALT cells are not regulated 




Figure 1.5: Regulated levels of TERRA through the cell cycle in telomerase positive cells is the 
main key to switch from (protected) closed to (replication) open status.  
 
Increased levels of TERRA through G1 and S act to sequester hnRNP A1, allowing RPA to replace POT1 and bind 
telomeric ssDNA. Downregulation of TERRA through S and S/G2 phases releases hnRNPA1, which in turn 
displaces RPA by binding telomeric ssDNA. TERRA levels increase in M/G1 to repeat the cycle. 
 
TERRA is required to establish telomeric heterochromatin in ALT cells 
Telomerase positive cells rely on the ATRX/DAXX complex to deposit H3K9me3, the 
signature of telomeric heterochromatin [75-78]. The absence of functional ATRX/DAXX 
complexes in ALT cells raises the question of how ALT cells compact telomeric chromatin. 
Montero, J.J., et al [122] proposed a model in which the level of TERRA works as a sensor to 
compact the chromatin. TERRA binds Polycomb Repressive Complex 2 (PRC2) and guides it to 
telomeres. TERRA-PRC2 at telomeres induces H3K27 methylation, which in turn facilitates 
recruitment of H3K9me3, H4K20me3, and anchoring of HP1to telomeric chromatin. However, 
neither PRC2 nor any telomeric heterochromatin marks were observed on 20q telomeres in 
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TERRA-knockout U2OS clones. These findings suggest that TERRA interacts with a variety of 
players to ensure end-capping and protection of chromosome ends [122]. 
TERRA maintain telomeres  
Emerging evidence suggests that the main role of regulated levels of TERRA is in telomere 
maintenance, as dysregulated levels of TERRA contribute to genome instability. To understand 
the role of TERRA in telomere maintenance, downregulation TERRA has been achieved in various 
cell lines utilizing a variety of approaches. The first attempt to deplete TERRA was in 2009, two 
years following its discovery. Small interference RNA (siRNA) mediated depletion of TERRA 
significantly reduced TERRA transcripts in U2OS cells measured by RNA-FISH, RNA dot-blot 
and Northern blot. [113]. In 2014 Lopez de Silanes, et al [115] employed LNA gapmeR AntiSense 
Oligonucleotide (ASO) to cleave mouse TERRA. Forty-eight hours post transfection with ASO, 
TERRA transcripts were measured by RT-qPCR and RNA dot-blot, which showed 50%reduction 
in total TERRA.  The same group targeted the TERRA locus on subtelomere 20q in U2OS cells 
utilizing CRISPR/Cas9 technology.  TERRA-20q U2OS clones displayed dramatic decreases in 
TERRA levels compared to parental U2OS cells [114]. In all mentioned studies [113] [114] [115], 
reduced levels of TERRA were associated with telomere fusions, telomere free ends, telomere 
duplications, telomere double minutes, and dysfunctional Telomere-Induced Foci (TIFs).  Such 
observations support a protective role of TERRA at telomeres by inhibiting the telomeric DDR via 
its role in telomere capping; specifically, by facilitating heterochromatin mark deposition and 
displacing RPA with the POT1-TPP1 complex [119]. Paradoxically, it has been shown that 
TERRA is involved in the telomeric DDR upon TRF2 depletion in HeLa cells. In TRF2 deficient 
HeLa cells, it was observed that TERRA molecules interacted with Lysine-specific demethylase 1 
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(LSD1). TERRA-LSD1 complexes increased the affinity of MRE11 to bind telomeric damage 
sites, process 3’ G overhangs, and sustain activation of ATM signals at uncapped telomeres [123].  
TERRA response to cellular stress 
Crosstalk between cellular stress and the DNA Damage Response (DDR) has been reported 
in many studies [124, 125].  In line with this notion, TERRA expression was induced in HeLa 
Wild Type (WT) cells upon incubating cells at 40 C° for an hour (Heat Shock). Strikingly, TERRA 
induction was dependent on recruiting the transcription factor Heat Shock 1 (HS1) to subtelomeres. 
However, TERRA induction was suppressed in HS1-knockout HeLa cells associated with 
telomeric DNA damage and detected TIF signals [126].  
Moreover, nutrient deprivation (culturing human colon cancer HCT116 cells in serum-free 
media) has also been shown to promote TERRA expression. Similar to what has been shown in 
HeLa cells, TERRA induction in HCT116 cells was also a dependent behavior. TERRA induction 
with nutrient deprivation was associated with the presence of p53 transcription factor, the key 
protein in tumor suppression. Notably, depletion of p53 subtelomeric binding sites prevented 
TERRA induction and induced telomere damage [127]. Such evidence suggests that TERRA is 
part of tumor suppressor network in response to cellular stress [128]. In another study, treatment 
of adenocarcinomic human alveolar basal epithelial (A549) cells with Bleomycine, a radiomimetic 
drug that induces DSBs, and measuring TERRA expression by PCR demonstrated elevated levels 
of TERRA [129]. It remains to be investigated whether TERRA is induced in response to other 
DSB-inducing agents like ionizing radiation (IR). In conclusion, findings to date suggest that 




DNA Double Strand Break repair pathways 
Cells experience DNA DSBs with exposure to IR or treatment with site-specific 
endonucleases. DNA DSBs are appreciated as the most lethal form of DNA lesion, and they 
contribute to genome instability and thereby cancer (reviewed in [130, 131]).  However, cells are 
equipped with an arsenal of different mechanisms to repair DSBs such as c-NHEJ, HR, alt-EJ and 
BIR reviewed in [132]. In the next section, we will briefly introduce each pathway and comment 
on their presence or absence when DSBs occur within telomeres.  
Classical non-homologous end joining (c-NHEJ) 
It has been well documented that c-NHEJ is the dominant DSB repair pathway in 
mammalian cells, particularly in G1 when a homologous template (sister chromatid) is not readily 
available. In S/G2 phases, c-NHEJ pathway proteins are expressed but the pathway itself is 
inhibited when Cell cYcle REgulator of NHEJ (CYREN) binds Ku70-Ku80 heterodimer (early c-
NHEJ pathway proteins) [133]. In response to DSBs and in the absent of CYREN, Ku70-Ku80 
heterodimers rapidly bind the DSB sites to stabilize the two ends and recruit the DNA-dependent 
protein kinase catalytic subunit (DNA-PKcs). Auto-phosphorylated DNA-PKcs phosphorylates 
ATM, and the histone variant H2AX on serine 139 to form γ-H2AX, the signature of DSBs.  
These critical phosphorylation events are required to initiate and sustain the DNA damage 
response so that the cell cycle slows down  [134]. Cells then commit to c-NHEJ when the 3′ to 5′ 
nucleolytic activity of MRE11, EXO1 and Artemis processes the two ends to generate two 3′ single 
stranded DNA overhangs, typically < 4bp. In c-NHEJ, extensive end resection is limited by 
binding of 53BP1, RIF1 and the shieldin complex [135]. Lastly, XRCC4 and Ligase IV align and 
ligate the two compatible ends. The c-NHEJ pathway results in deletion or insertion in the repaired 
product, and thus is considered as error- prone repair pathway.  
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Functional telomeres take advantage of shelterin proteins to prevent triggering of a 
telomeric DDR. TRF2 prevents ATM signaling and the c-NHEJ repair pathway via two 
mechanisms. TRF2 is sufficient for remodeling of the single-stranded telomeric G-rich overhang 
to form a T-loop – essential for preventing binding of the MRN complex and Ku70/80 heterodimer. 
TRF2 showed the ability to bind and block Ku70, preventing the tetramerization of Ku70/80 
complex and thereby preventing initiation of c-NHEJ [132, 134]. 
Homologous Recombination (HR)   
When sister chromatids are available after replication, 53BP1 is antagonized by BRCA1 
allowing for extensive resection >100 bp [136]. Resection is promoted by the activity of 
endonuclease protein MRE11, one of the members of the MRN complex (MRE11-RAD50-NBS1) 
and the C-terminal binding protein interacting protein (CtIP), EXO1 and DNA2 helicase/nuclease. 
Following resection, the two ss-DNA ends become coated with RPA, which is eventually replaced 
with Rad51 [137].  Rad51-coated DNA invades and anneals to the homologous template forming 
holliday junctions. Lastly, DNA polymerase binds the 3’ end of the invading allowing DNA 
synthesis and eventually resolving holliday junctions [138]. HR is considered less error-prone 
pathway that utilizes a homologous template. Comparison reports between telomerase positive 
cells and ALT cells have shown that HR is elevated in ALT cells due to reduced shelterin saturation 
[78, 132].  
Alternative-End Joining (alt-EJ) 
In addition to studies characterizing the pathways of C-NHEJ and HR, Liang and Jasin 
discovered alt-EJ as an alternative pathway to compensate for the loss of C-NHEJ pathway in 
XRCC4 or Ligase IV deficient cells [139, 140]. However, different studies have shown that Alt-
EJ occurs in C-NHEJ proficient cells as well [141]. Mechanistically, Alt-EJ starts with processing 
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the two ends to expose microhomology that < 21 bp using the same proteins that used in HR. Next, 
the two main proteins in this pathway poly (ADP-ribose) polymerase 1 and polymerase θ 
(Polθ) facilitate DNA synapsis and strands annealing.  Following the annealing, nuclease enzymes 
remove the non-complementary 3’ flap and Ligase 1 and Ligase 3 ligate the two ends [141-143]. 
In cancer cells, Alt-EJ pathway have been implicated in insertions, deletions and chromosome 
fusions. In particular, recent studies have demonstrated that removing TRF2 or POT1/TPP1 
shelterin protein from telomeres in Ku70/80 deficient cells results in a mild telomere fusions 
phenotype.  Telomere fusions were observed involving every telomere after depleting all shelterin 
proteins in Ku70/80 deficient cells [4, 144]. 
Break-induced Replication (BIR) 
BIR differs from the HR DSB repair pathway due to its unique ability in repairing DSBs 
with only one end. The BIR pathway has been discussed in a previous section. 
The choice of the appropriate pathway can be determined firstly by the cell cycle phase in 
which the DSBs occurs [133]; the cell cycle takes a leading role in regulating the DNA end 
resection following the damage [145].  In G1 phase, the end- resection independent pathway NHEJ 
is the dominant pathway. Recent studies show that inhibition of resection in G1 has been associated 
with the activity of RPA-DNA Helicase B complex. This complex works, independently of 53BP1, 
to prevent the binding of exonuclease-mediated resection proteins including; EXO1, and BLM-
DNA2 [146].  It is also well documented that expression of HR genes is downregulated in G1 
phase [147]. In G2 phase, the opposite scenario was reported to promote the end- resection 
dependent pathways HR or alt-NHEJ [147].   
In addition to cell cycle phase, accumulated evidence implies the sequence context at the 
DSB site can also impact the choose of the repair pathway [148]. NHEJ pathway has been shown 
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to be strictly blocked within telomeres through the cell cycle [96, 97, 130]. Alternatively , 
telomeric hyper resection HR and telomeric hypo resection alt-EJ pathways have been utilized by 
cells to repair the telomeric DSBs [96, 97, 130]. 
The balance between telomere protection and telomere repair in mammalian cells 
The highly protective system of inhibiting DDRs and repair within telomeres made 
biologists question how telomeric DSBs are repaired following damage within telomeres 
themselves.  Early experiments exposed proliferating fibroblasts to high doses of IR (10, 20 Gy, 
X-rays) to induce DSBs genome wide. [149]. Interestingly, while DNA damage at non-telomeric 
sites decreased over time, targeted telomeric DNA damage accumulated, indicating that telomeric 
DSBs are irreparable [149] . The main pitfall of using this approach is the need of extremely high 
doses of IR to generate DSBs within relatively rare telomeric DNA, which may alter gene 
expression and/or cause mitochondrial dysfunction/oxidative stress, known contributors to 
telomere damage [130, 131]. Thus, IR exposure cannot discriminate whether the detected 
telomeric damage response is a result of DSB within telomere sites or the indirect impact of high 
doses on telomeres. To address this obstacle and answer the question, telomeric site-specific 
endonucleases have been developed and employed in recent studies.  Expression of FokI-TRF1, 
and Cas9 in mouse fibroblasts and human ALT cancer cells, results in TIFs (broken telomeres) 
with no associated loss of telomeres or telomere fusions in metaphases spreads, indicative of the 
ability of the cells to repair DSBs within telomeres, independent of c-NHEJ [96, 97, 150-152].  
Other supportive evidence for the strict prevention of c-NHEJ following endogenous 
telomeric DSBs has been reported after expressing FokI-TRF1 in Lig4-/- mouse cells. Frequencies 
of TIFs in Lig4-/- mouse embryonic fibroblasts (MEFs) were not altered compared to TIFs 
following damage in WT-Lig4 control cells [151]. Our studies also found no evidence of c-NHEJ 
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following telomeric DSBs generated via transient transfection of the silkworm endonuclease 
TRAS1-EN (ENT) fused to TRF1 to target telomeres in human BJ1-hTERT fibroblasts and EJ-30 
telomerase positive cancer cells (unpublished). Because c-NHEJ is the dominant repair pathway 
in G1, we monitored localization of 53BP1 at telomeric DSBs in G1. The lack of 53BP1 at 
telomeric damage sites, both in the presence of TRF2 and after depleting TRF2, supports 
suppression of c-NHEJ in G1 human fibroblasts and cancer telomerase positive cells. This 
hindrance to the c-NHEJ pathway within telomeres is attributed to the fact that c-NHEJ can 
contribute to genome instability [130, 153]. 
Since c-NHEJ is not the preferred pathway of DSB repair within telomeres, resection 
dependent repair pathways (HR, alt-EJ and BIR) were also investigated. Although we observed 
that fibroblast and telomerase positive cells undergo extensive resection in G1 following induced 
telomeric-specific damage, neither BIR-induced HR repair proteins, nor DNA synthesis was 
detected (unpublished). 
While similar findings in G1 HeLa cells have been reported, sustaining TIF signals upon 
depleting PARP1 or Lig3 suggests potential participation of alt-EJ pathway at telomeric DSB in 
MEFs cells [151]. The repetitive nature of telomeric regions may make alt-NHEJ an attractive 
option for repairing telomeric DSBs.   
 In contrast to alt-EJ in fibroblasts, endonuclease-induced telomeric DSBs have been 
implicated in triggering extensive resection, homology-searching and pairing interaction between 
sister chromatids in S phase and non-sister telomeres in G1 phase and DNA synthesis in ALT cells 
[96, 97, 150]. Inhibiting or depleting Rad51 precludes the physical interaction between non-sister 
telomeres and thereby telomere shortening [96]. Cells exposed to long-term telomeric DSBs 
preferentially utilize recombination between non-sister telomeres, rather than sister chromatids, to 
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elongate telomeres [96, 97, 150]. Thus, telomeric recombination can occur between non sister 
telomeres in G1 when sister chromatids are not available. 
At present, it appears that alt-EJ or BIR-induced HR may be involved in repair of telomeric 
DSBs in human ALT and non-ALT cells. However, whether TERRA plays a role in telomeric 
DSB repair has not been elucidated.  Our work here revealed for the first time an increase in 
TERRA in response to IR exposure, as well as colocalization of TERRA at telomeric DSBs 
following induction of telomere-specific damage. 
27 




Telomeres are special nucleoprotein structures at the ends of linear chromosomes [2, 3].  
In humans, telomeres consist of 5-15 kb of repetitive DNA sequence (5’-TTAGGG-3’) bound by 
a specific protein-complex known as shelterin, made up of TRF1, TRF2, TIN2, TPP1, RAP1, 
POT1, and TZAP [8-12].  Due to the inability of conventional polymerases to replicate to the very 
end of linear DNA molecules (the end-replication problem), the telomeric G-rich strand ends with 
a 3’ single-stranded (ss)overhang [16].  TRF2 has been shown to play a role in looping and 
facilitating invasion of the 3’ (ss)overhang into telomeric double stranded (ds)DNA, forming a T-
loop [15], an effective solution to the end-protection problem [26].   
Telomerase is the specialized reverse transcriptase (TERT) capable of de novo elongation 
of telomeres [35].  Telomerase activity is significantly reduced in normal somatic mammalian cells 
[37]. Hence, telomeres shorten with cell division, and therefore with aging. Furthermore, as 
telomeres become critically short, they activate cell cycle checkpoints, cell cycle arrest, and 
senescence or apoptosis [52].  In contrast, ~85-90 % of cancers reactivate telomerase to maintain 
telomere length and enable unlimited cell division, some by way of mutations in the promoter of 
TERT [54]. The remaining ~10-15% of cancers maintain telomere length via an homologous 
recombination (HR)-mediated Alternative Lengthening of Telomeres (ALT) pathway [68, 81, 86].  
Telomeres are transcribed into the telomeric long noncoding RNA TERRA, which is 
transcribed from start sites (CpG islands) originating within subtelomeric regions [20]. While a 
proportion of TERRA is found bound to telomeres, the remainder is not associated with telomeric 
chromatin  [25, 154].  Interestingly, ALT cells have elevated levels of TERRA as compared to 
 
28 
telomerase positive cells [100].  In vitro and in vivo studies have shown that TERRAs is involved 
in maintaining both telomere length and telomere protection [113, 121, 122, 128].   
It has also been demonstrated that conventional DNA repair is inhibited at telomeres [108].   
Misrepair or non-repair of deleterious DSBs, such as those induced by ionizing radiation (IR) 
exposure, is known to give rise to chromosomal aberration and genomic instability[132] . This 
prompted us to investigate how human cells handle DSBs occurring within telomeres themselves.  
Understanding DSB repair within telomeres has become an intriguing topic, investigated by many 
research groups [96, 97, 130, 151].  However, the role of telomeric RNA (TERRA) is not well 
understood.  
Here, we hypothesized that TERRA plays a role in repair of telomeric DSBs.  To test this, 
we utilized human U2OS (ALT) cells, which have high levels of TERRA.  Our aims included 
characterizing TERRA response to global DNA DSBs induced by IR, as well as to enzymatically-
induced DSBs targeted specifically to telomeres. 
Increased TERRA following Ionizing Radiation exposure 
Increased TERRA transcription following treatment with Bleomycine, a radiomimetic drug 
that induces DSBs, has been demonstrated [129]. We investigated whether TERRA might also be 
influenced by IR exposure, a potent inducer of prompt DSBs.  RNA FISH analysis revealed a 
significant increase in the number of TERRA foci in U2OS cells exposed to 2 Gy γ-rays compared 
to unirradiated controls (Figure 2.1 A, B). To validate these findings, irradiated and unirradiated 
U2OS cells were also treated with RnaseA and RnaseH to remove TERRA; TERRA foci were 
significantly diminished (Figure 2.1 C,D).  Results demonstrate that TERRA responds to IR 











Figure 2.1: TERRA and IR in cycling U2OS (ALT) cells.  
 
A, B, C. TERRA foci were significantly increased four hours after IR exposure (2 Gy) compared to 0 Gy controls. 
Treatment with RnaseA + RnaseH removed TERRA from irradiated and unirradiated cells.  D, Quantification of 
nuclear TERRA foci; 3 experiments each (n = 50), error bars represent SEM. T test  ***P < 0.001; **P < 0.01; *P < 
0.05.  
 
Telomere-specific DSBs induce telomeric DDR involving TERRA  
To better understand ALT DDRs involving TERRA at telomere-specific DSBs, we 
employed our validated system utilizing transient transfection of a plasmid encoding a flag-tagged 
telomere repeat-specific endonuclease fused to the human TRF1 gene (TRAS1-EN-TRF1: 
hereafter referred to as ENT-TRF1) that produces blunt ended DSBs within telomeres [155, 156].  
Here, we used the EN-T system in U2OS (ALT) cells to characterize the telomeric DDR to targeted 
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DSBs.  For controls, U2OS cells were transfected with plasmids that expressed TRF1-only, empty 
vector, or were un-transfected.  In experiments interrogating TERRA, a combination of Rnase A 
and Rnase H was used to remove TERRA as a negative control.  
First, we sought to establish transfection efficiencies in U2OS cells, determine phase of the 
cell cycle in which cells accumulate following transfection, and establish TERRA response to 
cellular stress of transfection. Additionally, we confirmed and quantified ENT-TRF1 induction of 
telomeric DSBs via co-localization of telomeres, EN-T (FLAG) and the DSB marker γ-H2AX, 
evaluated whether TERRA co-localized at telomeric DSB sites via co-localization of TERRA and 
FLAG, and evaluated potential role of the cell cycle on TERRA recruitment to damaged telomeres.  
Distinguishing cell cycle phase in FUCCI - U2OS interphase cells  
In order to monitor the effects of transfection on TERRA distribution throughout the cell 
cycle, we employed a Fluorescent Ubiquitination-based Cell Cycle Indicator (FUCCI) strategy to 
readily distinguish G1, S, and G2 phase in interphase nuclei. A stable U2OS cell line expressing 
Geminin protein fused to Green Fluorescence Protein (Geminin-GFP) [157] was generated to 
positively identify cells in G2 phase.  Colocalization of the G2 markers Geminin-GFP and 
Centromere protein F (CENP-F) confirmed that the FUCCI plasmid had not been lost, and that 
absence of Geminin-GFP signals in each negative (unlabeled) cell represented a cell in G1 or S 
phase.  Results also confirmed that cells labeled with CENP-F were also positive for Geminin-
GFP and so were in G2, and cells negative for CENP-F did not express Geminin-GFP and so were 
in G1/S (Figure 2.2 A).  To definitely label cells in S phase, cells were incubated with EdU for 30 








Figure 2.2: FUCCI – U2OS cell line to identify cell cycle phase.  
 
A. Co-localization of nuclear CENP-F protein (red) and Geminin-GFP (green) in U2OS cells stably expressing 
Geminin-GFP confirms that the FUCCI plasmid had not been lost, and that negatively staining cells (blue) were in G1 
or S.  B. Simple schema for discriminating cell cycle in interphase nuclei: G1 cells negative for EdU and Geminin-
GFP/CENP-F (blue); S phase cells positive for EdU (red); G2 cells positive for Geminin-GFP/CENP-F (green). 
 
Transfection efficiencies in FUCCI- U2OS cells 
Utilizing lipofectamine, populations of U2OS cells expressing FUCCI were transfected 
with either ENT-TRF1, TRF1-only, or empty vector, and as a negative control, no transfection. 
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Following transfection (48 hr), FUCCI-U2OS cells were fixed, and Anti- FLAG antibody used to 
evaluate transfection efficiencies. Transfection efficiencies of ~25-30% were observed (Figure 
2.3A). There were no significant differences in average number of FLAG foci in cells transfected 
with ENT-TRF1 or TRF1-only (Figure 2.3B).  
The low efficiency of transient transfection in U2OS cells may be attributable to the 
particular cell line, and/or the lipid-based delivery method used, which does have lower efficiency 
compared to viral-based delivery approaches. Another consideration is that cells were fixed 48 
hours after transfection using Lipofectimine 2000, while expression of the gene starts 6-8 hours 
after transfection. The number of expressed FLAG foci in FUCCI-U2OS cells transfected with 
ENT-TRF1 or TRF1-only did not show any significant difference, indicating that the two different 













Figure 2.3: FUCCI-U2OS transfection efficiencies.    
 
A. Representative images of transiently transfected FUCCI-U2OS cells co-stained for nuclei (DAPI; blue) and 
(FLAG; red).  B. Quantitation of average number FLAG foci/cell. Data represent 3 experiments each; error bars are 
SEM (n = 12-200). Significance of one-way ANOVA and Holm-sidak Test ***p,0.001; **p<0.01; *P<0.05. ns, not 
significant 
 
FUCCI-U2OS cells accumulate in G2 following transfection 
We have previously shown that normal human, non-ALT BJ1-hTERT fibroblasts 
transfected with ENT-TRF1 or TRF1-only arrest in G1 (manuscript under review). Here we find 
that FUCCI-U2OS cells transiently transfected with ENT-TRF1, TRF1- only, or empty vector 
accumulate in G2 compared to untransfected cells; specifically, 48 hour following transfection the 
fraction of cells in G2 increased (Figure 2.4 A, B). The enrichment of positively transfected cells 
in G2 phase suggests that transfected cells undergo DNA damage and /or cellular stress response.  













Figure 2.4: FUCCI-U2OS cell cycle distribution following transfection.   
 
A. Representative images of untransfected FUCCI-U2OS cells labeled with only DAPI (G1 phase), EdU (S phase), 
Geminin-GFP and CENP-F (G2 phase), FLAG (untansfected), merged views with DAPI (blue) B. Representative 
images of transiently transfected FUCCI-U2OS cells labeled with with only DAPI (G1 phase), EdU (S phase), 
Geminin-GFP and CENP-F (G2), FLAG (transfected), and merged views with DAPI (blue). C. Histogram represents 
the relevant percentage of FUCCI-U2OS cells in each cell cycle phase with and without transfection. Data was 
analyzed from 3 experiments. 
 
TERRA distribution in FUCCI-U2OS cells following transfection 
Next, we examined the effect of transient transfection of ENT-TRF1, TRF1-only, and 
empty vector on the distribution of TERRA through the cell cycle in FUCCI-U2OS cells. Total 
TERRA foci were evaluated by RNA-FISH in positively (25-30%) and negatively (65-70%) 
transfected cells for each treatment and compared to un-transfected controls. Consistent with the 
cell cycle profiles, TERRA foci were highly enriched in G2 compared to un-transfected cells 
(Figure 2.5 A, B, C). Treatment with RnaseA and RnaseH diminished TERRA signals, confirming 
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TERRA presence (Figure 2.5 D, E). The accumulated levels of total TERRA in G2 positively 
transfected as compared to un-transfected control cells suggest TERRA involvement in the DNA 





















Figure 2.5: TERRA accumulates in G2 following transfection.   
 
A. Representative images of transiently transfected FUCCI-U2OS cells labeled for FLAG and TERRA. Total TERRA 
was scored in positively (25-30%) and negatively (65-70%) transfected cells from each treatment B. Representative 
images of transiently transfected FUCCI-U2OS cells stained for EdU (S phase), Geminin-GFP and CENP-F (G2), 
FLAG, or TERRA, and merged views with DAPI (blue). B. Representative images of transiently transfected FUCCI-
U2OS cells stained for EdU (S phase), Geminin-GFP and CENP-F (G2), FLAG, or TERRA, and merged views with 
DAPI (blue).  C.  Histogram shows the corresponding percent of TERRA in each cell phase with and without 
transfection.  D. Representative images of transiently transfected FUCCI-U2OS cells, treated with Rnase A and Rnase 
H and labeled for EdU, Geminin-GFP and CENP-F, FLAG, TERRA and merged views with DAPI.  F. Histogram 
shows the corresponding percentage of TERRA in each cell phase with and without transfection. Data was analyzed 




Telomere-specific DSBs in FUCCI-U2OS cells 
The enrichment of transfected cells and accumulation of total TERRA in G2 phase 
provided evidence that transfected cells experienced DNA damage. Combining telomere FISH 
with fluorescence immunostaining against FLAG and the DNA DSB marker γ-H2AX (FLAG/γ-
H2AX/Telomere co-localized foci) confirmed that ENT-TRF1 localized to telomeres and induced 
telomere-specific DSBs. Consistent with previous reports in telomerase positive cells [160-162] , 
we also observed that overexpression of TRF1 induced telomeric DSBs in ALT cells.  Only cells 
with > 20 FLAG foci were counted as positive transfected cells (Figure 2.6 A, C). Taken together 
with the absence of γ-H2AX foci in cells transfected with empty vector or untransfected cells 
(Figure 2.6 B), results validated that expression of ENT-TRF1, or TRF1-only, in FUCCI-U2OS 
cells induces telomere-specific DSBs. Consistent with expectation, treatment with RNAse A + 











Figure 2.6: Telomere-specific DSBs in FUCCI-U2OS cells.  
 
A. Representative images of FUCCI-U2OS cells transfected with empty vector and untransfected cells, and then 
labeled for FLAG, γ-H2AX- and telomeres, and merged images with DAPI (blue) confirming induction of telomeric 
DSBs.  B. Representative images of FUCCI-U2OS cells transfected with either ENT-TRF1 or TRF1 only, and then 
labeled for FLAG, γ-H2AX- and telomeres, and merged images with DAPI (blue) confirming induction of telomeric 
DSBs. C.  Histogram represents the corresponding percentages of colocalized foci in cells with >20 FLAG foci (n= 




TERRA accumulates at telomere-specific DSBs  
We then evaluated the question of whether TERRA participated in the telomeric DDR by 
responding to telomeric DSBs in FUCCI-U2OS cells. To ensure that TERRA-FLAG 
colocalization events (broken telomeres) were induced by ENT-TRF1 or TRF1-only, scoring was 
restricted to positively transfected ENT-TRF1 and TRF1-only cells (Figure 2.7A). In order to 
visualize TERRA at telomeres in cells transfected with empty vector or un-transfected cells that 
lack FLAG, another means of detecting telomeres was necessary.  The telomere-specific binding 
factor TRF2 was selected, as this approach was compatible with RNA-FISH (Figure 2.7 B).  
Although FLAG signals from ENT-TRF1 and TRF1-only populations colocalized often with 
telomeres (Figure 2.6 C, D), fewer telomeric FLAG signals were detected using TRF2 (Figure 
2.7 C). This can likely be attributed to the observation of faint or absent TRF2 fluorescent signals 
in some positively transfected ENT-TRF1 and TRF1-only cells compared to TRF2 signals in 
controls (Figure 2.7 C).  Three distinct TERRA colocalization events were detected in ENT-TRF1 
and TRF1-only populations: TERRA-TRF2, FLAG-TRF2(telomere)-TERRA, and FLAG-
TERRA (Figure 7 C, D).  Results clearly demonstrated that TERRA accumulates at telomeric 
DSBs, a finding supported by treatment with RnaseA and RnaseH, which removed TERRA signals 
(Figure 2.7 E). Summing up the average number of foci for the three different types of TERRA 























Figure 2.7: ERRA accumulates at telomeric DSBs.    
 
A. Representative images of transiently transfected FUCCI-U2OS cells labeled for FLAG and TERRA. Hybridized 
TERRA was scored in only positively (25-30%) transfected cells from each treatment B. Representative images of 
untransfected and empty vector transfected FUCCI-U2OS cells labeled for FLAG, TERRA (grey), and TRF2 
(telomeres, green), and merged views with DAPI (blue). C. Representative images of transiently transfected FUCCI-
U2OS cells labeled for FLAG (red), TERRA (grey), and TRF2 (telomeres, green), and merged views with DAPI 
(blue). D. Histogram represents the average number of foci (TERRA-TRF2, FLAG-TRF2-TERRA, or FLAG-
TERRA)/cell.  E. Histogram represents the average number of foci/cell following treatment with Rnase A and H. Data 








TERRA plays a protective role at telomeric DSBs 
Our unpublished work showed that induction of targeted telomeric DSBs in normal human 
G1 non-ALT fibroblasts (BJ1-hTERT), which have low levels of TERRA compared to ALT 
(U2OS) cells, was associated with a significant increase in 5’ C-rich single-stranded (ss)telomeric 
DNA (manuscript in preparation/under review). Interestingly, extensive resection was not detected 
in BJ1-hTERT cells transfected with TRF1-only. Here, we present evidence that transfecting 
FUCCI-U2OS cells with either ENT-TRF1 or TRF1-only induces telomeric DSBs, and further 
that TERRA accumulates at the damage sites (Figure 2.6 B, C). Utilizing native (non-denaturing) 
DNA FISH to detect 5’ C-rich (ss)telomeric DNA in FUCCI-U2OS transfected cells, combined 
with immunostaining to detect FLAG in cells presumably in G1 (negative for green FUCCI, so 
not in G2), no induction of C-rich (ss) telomeric DNA was observed (Figure 2.8 A, C).  However, 
treatment with RnaseA and RnaseH to remove TERRA (5’-UUAGGG-3’) revealed a significant 
increase in telomeric resected C-strands (5’-CCCTAA-3’) in cells transfected with ENT-TRF1, 
but not with TRF1-only (Figure 2.8 B, C). Taken together, these results suggest a protective role 
for TERRA at telomeric DSB sites in G1, as well as a different mechanism of telomeric repair in 








Figure 2.8: Transfection of FUCCI-U2OS cells with ENT-TRF1 and removing TERRA revealed  
significant induction of 5’ C-rich single-stranded (ss)telomeric DNA 
 
A. Representative images of transiently transfected FUCCI-U2OS cells labeled for ENT-TRF1 or TRF1 only using  
FLAG (red), C-strand telomeric sequence (AATCCC) using  G-rich probe (green), and merged views. B. 
Representative images of transiently transfected FUCCI-U2OS cells, treated with RnaseA+RnaseH, and labeled for 
ENT-TRF1 or TRF1 only using FLAG (red), C-strand telomeric sequence (AATCCC) using G-rich probe (green), 
and merged views.  C. Quantitation of average number telomeric C-strand foci. Data represents three experiments and 
values are expressed as SEM (n = 120-200). One-way ANOVA and Holm-sidak Test ***p,0.001; **p<0.01; *P<0.05. 
ns, not significant  
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Over the last decade, transcription of telomeres has been intensely investigated. Since its 
discovery, heterogeneous lengths of the telomeric RNA TERRA (3’-UUAGGG-5’) have been 
visualized in yeast, human and mouse [20, 108, 110]. The discovery of TERRA was corroborated 
by Chromatin immunoprecipitation analysis, which also revealed RNA pol II binding at various 
subtelomeric promoter sites [109, 112].  Functionally, TERRA has been shown to be involved in 
telomere replication [81, 120], telomere protection [109, 114, 115, 122], telomeric 
heterochromatin mark deposition [23] , and telomere length maintenance by homologous 
recombination (HR) [100].  Human cancer cells that maintain their telomeres using the telomerase-
independent ALT pathway are characterized by a number of hallmarks [163], including elevated 
levels of TERRA [81-83], and telomere length maintenance via a HR-dependent mechanism [96, 
97, 150]. Indeed, work by Arora et al has shown that TERRA promotes HR in human 
osteosarcoma U2OS (ALT) cells [100].  However, the role of TERRA in response to DNA damage, 
and specifically in response to telomeric DSBs, has not been elucidated.   
TERRA in response to genomic DNA DSBs   
Ionizing radiation (IR) is a well-established inducer of prompt DSBs. We investigated the 
response of TERRA to genomic DNA DSBs resulting from IR exposure (2Gy; γ-rays) in U2OS 
(ALT) cells. Interestingly, TERRA foci were significantly increased in irradiated vs. non-
irradiated control cells (Figure 2.1).  This finding is consistent with a recent study reporting that 




However, considering the small fraction of the genome that telomeric DNA represents, this 
relatively low dose of IR would be expected to directly “hit” and “break” telomeres only very 
rarely.  Therefore, we employed an approach to enzymatically-induce telomere-targeted DSBs 
using the endonuclease ENT fused to the telomeric protein TRF1, which was developed and 
validated in U2OS cells [164].   
TERRA in response to transient transfection  
We employed a FUCCI-based system to positively identify cell cycle phase of interphase 
nuclei, which revealed that the stress of transient transfection significantly influenced U2OS cell 
cycle profiles.  Cell cycle analyses demonstrated that transfected cells accumulate in G2 (Figure 
2.4 ), similar to the G2 arrest observed following exposure to IR [165], or treatment with the 
radiomemetic drug-neocarzinostain [166, 167]. A linear correlation between the amount of DNA 
damage induced, and the stringency of the activated G2 checkpoint/halting of cell cycle 
progression, has been previously demonstrated in U2OS cells [166, 167].  A permissive G1/S 
checkpoint in U2OS cells, resulting from truncated WIP1(wild-type p53-induced phosphatase 1) 
and p16 deficiency (a cyclin-dependent kinase inhibitor essential for regulating the cell cycle), also 
likely contributes to the enrichment of G2 cells observed  [158, 159].  
We then evaluated whether TERRA levels were elevated in G2 phase following 
transfection. Consistent with the cell cycle analysis, the distribution of total TERRA shifted, 
accumulating in G2 in response to induction of telomeric DSBs and/or the stress stimuli of 
transfection (Figure 2.5).  It has been previously shown that adenovirus-mediated transfection of 
U2OS cells with ENT-TRF1 activates a p53-dependent pathway [164], and that activation of 
subtelomeric p53 in response to cellular stress can induce TERRA transcription [127]. A more 
recent study demonstrated a direct role for long non-coding (lnc)RNA p53-induced NC RNA 
 
50 
(PINCR) in G1 arrest in colorectal cancer cells; PINCR was found to regulate the expression of 
genes implicated in G1 arrest [168].  Several p53-induced lncRNAs, including LED, p53- 
regulated lncRNA (PR lncRNA), and lncRNA p21, have been shown to be required for checkpoint 
activation and cell cycle arrest; reviewed in [169].  Considering that U2OS cells are p53 positive 
[170] and have a disrupted G1 checkpoint [158, 159], accumulation of TERRA in G2 following 
transfection (ENT-TRF1 or TRF1-only) supports TERRA responsiveness to p53, as well as 
suggests a potential role for TERRA in activation of the G2 checkpoint in U2OS (ALT) cells.  
TERRA in response to telomere-specific DSBs 
We validated the telomere-targeting/DSB-inducing capabilities of the ENT-TRF1 system 
in U2OS (ALT) cells [164]. Since ENT-TRF1 also increases endogenous levels of TRF1, FUCCI-
U2OS cells transfected with a TRF1-only plasmid that overexpressed TRF1 were used as a control.  
Consistent with previous reports, TRF1-only also induced co-localization with γ-H2AX, 
indicative of telomeric DSB induction (Figure 2.6 ), which could be due to the fact that TRF1 
plays a critical role in telomere protection and telomere length regulation [160-162].  In particular, 
telomerase positive cells overexpressing TRF1 experience telomere shortening [160], telomere 
bridges, and DNA DSBs [171].  In telomerase independent ALT cells, it has been shown that non 
telomeric phosphorylated (T371)TRF1 is crucial for promoting homologous recombinational (HR) 
repair upon induction of global DNA damage (IR exposure) [172].  Furthermore, overexpression 
of TRF1 in TRF1 knockdown ALT cells suppressed the reduction of C-circles [173], which have 
been associated with HR activity [97].  Our results provide additional support for a role of TRF1 
in promoting telomeric HR following induction of telomeric DSBs.   
Our controls (empty vector and un-transfected) required a different shelterin component in 
order to visualize potential hybridization of TERRA to telomeres in control populations; the 
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telomere repeat factor 2 (TRF2) was selected. Again, a significant increase of TERRA co-
localized at broken telomeres was observed in U2OS cells expressing ENT-TRF1 and TRF1-only 
(Figure 2.7).  It is also worth noting that the TERRA detected here was hybridized (co-localized) 
at telomeric DSBs (Figure 2.7).  Hybridized TERRA at telomeric DSBs is distinct from 
free/unbound TERRA (foci not co-localized at telomeres), which was detected in response to 
transfection (Figure 2.4) and in cells transfected with empty vector. 
TERRA is required to protect telomeric DSBs in G1 cells 
Our previous work in normal G1-human fibroblasts, which have low levels of TERRA, 
demonstrated increased frequencies of 5’ C-rich single-stranded (ss)telomeric DNA (indicative of 
extensive resection) at telomeric DSB sites (manuscript under review). In light of the 
complementary sequence of TERRA, we hypothesized that hybridized TERRA at telomeric DSBs 
in ALT cells may well protect the exposed C-rich (ss)overhangs from being extensively resected. 
Consistent with such a notion and with our previous findings, a significant induction of 5’ C-rich 
(ss)telomeric DNA was observed in G1 U2OS (ALT) cells experiencing ENT-TRF1 induced 
DSBs (Figure 2.8), (Figure 3.1).  
Emerging evidence, in both yeast and mammalian cells, supports a link between 
RNA:DNA hybrids and DNA end resection. For example, inhibiting DNA-end resection by 
knocking down either EXO1 or CtIP after inducing a site-specific DSB in U2OS cells impairs 
formation of RNA:DNA hybrids [174]. In  Schizosaccharomyces pombe, RNA:DNA hybrids at 
DSBs have been shown to limit resection of ssDNA and regulate the binding of replication protein 
A (RPA) [175]; overexpression of Rnase H1 stabilized RNA:DNA hybrids and impaired 
recruitment of RPA [175].  Phosphorylated RPA at (ss)telomeric DSB sites in G1 human cells was 
also observed in our previous work. Of relevance in this regard, a recent work identified RPA as a 
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sensor of RNA:DNA hybrids in non-S phase HeLa cells [176]; RPA enhanced the binding of 
RnaseH1 and RNA:DNA hybrids [176]. Additionally, stabilized RNA:DNA hybrids at I-SceI-
induced DSBs in U2OS cells have been observed to avert RPA binding [177]. Removal of RNA 
from RNA:DNA hybrids significantly reduced BRCA1 and RAD51 recruitment in G2 [174].  
Interestingly, in contrast to the extensive resection observed at ENT-TRF1 induced 
telomeric DSBs and the evidence in support of HR-mediated repair in G2, only minimal resection 
was detected at broken telomeres induced by TRF1-only, potentially implicating alt-EJ in their 
repair [130]. In either case, hybridized TERRA would be expected to protect the vulnerable 
(ss)telomeric overhangs.  
Although the role of long noncoding (lnc)RNA in response to genomic DSBs has been 
recently investigated, our data are the first to demonstrate a role for the telomeric lncRNA, TERRA, 
in telomeric DSB repair.  We propose that TERRA binds exposed 5’ C-rich (ss)telomeric DNA at 
extensively resected telomeric DSBs, presumably to preserve/protect them until S/G2 when HR-




Figure 3.1: Telomeric RNA TERRA protects exposed ss telomeric DNA. 
 
Expression of ENT-TRF1 induces blunt ended telomeric DSBs in U2OS (ALT) cells results in extensive resection 
and generating C-rich overhangs which protected by pairing to telomeric RNA (TERRA) in G1.  Previous work 
demonstrated that telomeric DSB-induced hyper resection can be repaired via HR [151]. Our model here also showed 
that over expression TRF-only induces telomeic DSBs by unknown mechanism. Although hybridized TERRA was 
accumulated at the damage sites, the C-rich overhangs was not detected in G1. The accumulated TERRA and 
undetectable resection provide another strong evidence for what has been reported; that U2OS-ALT cells repair 
telomeric DSBs damage in G2 via alt-EJ pathway which require limited resection and perfect homology within 
telomeres sequences [151]. Finally, while  POT1was suggested to  protect G-strands [151]our model illustrates the 
role of TERRA in protecting C-strands in G1.  
 
Conclusion 
In summary, the work presented here provides evidence supportive of a role for the 
telomeric RNA TERRA in response to telomeric DNA DSBs in U2OS (ALT) cells. IR-induced 
genomic DSBs increased frequencies of TERRA foci. Furthermore, enzymatically-induced 
telomere-specific DSBs resulted in increased co-localization of (bound) TERRA to broken 
telomeres.  ALT (U2OS) cells experiencing telomeric DSBs accumulated in G2, as did TERRA; 
cells also accumulated in G2 in response to the cellular stress of transfection. TRF1-only induced 
telomeric DSBs resulted in TERRA accumulation at the break sites, but no (ss)telomeric DNA was 
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observed. A protective role of hybridized/bound TERRA at resected telomeric DSBs in G1 human 
cells is proposed, which likely contributes to preserving vulnerable (ss)telomeric DNA until G2 
when HR-mediated elongation/repair is a possibility.   Our work also provides additional support 








The work reported here characterizes the response of the telomeric lncRNA, TERRA, in 
the DNA damage response, specifically to DSBs induced by either ionizing radiation (globally) or 
targeted specifically to telomeres (ENT-TRF1) in human U2OS (ALT; telomerase independent) 
cells. TERRA levels were elevated following induction of DSBs by both treatments.  Our results 
revealed that TERRA associates with telomeric DSB sites (suggestive of TERRA: telomere DNA 
hybrids), and that cells suffering telomeric DSBs accumulate in G2.  We also found evidence in 
support of a role for hybridized TERRA in protecting (ss)telomeric DNA in G1.  
Methodological limitations of the current study include low transfection efficiencies in 
U2OS cells utilizing the ENT-TRF1 plasmid-based approach, and losing expression of the vector 
in a majority of cells 72 hours after transfection. Therefore, establishment of a tetracycline (Tet)-
inducible (On/Off) U2OS (ALT) cell line expressing ENT-TRF1 would represent a valuable 
improvement, as it would facilitate stable levels of transfection and control of expression.  
Although treatment with RnaseA and RnaseH in combination as performed here effectively 
removed TERRA, more permanent depletion of TERRA would also be an important next step in 
analyzing the response to telomeric DSBs – in both ALT and telomerase positive cancer cells.  
Development of CRISPR-Cas9 genome editing strategies against TERRA would be an important 
advancement, as it would facilitate additional analyses on repair pathway choice (e.g., HR-BIR, 
alt-EJ) and telomere length dynamics (changes over time).   
In light of recent controversy regarding the chromosomal origin(s) of TERRA [114, 116] 
it would be of particular interest to characterize and identify specific TERRAs responding to 
telomere DNA damage; are such TERRA transcripts unique?  It might be possible to identify them 
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based on unique sub-telomeric sequences they possess, which could be determined using state-of-
the-art RNA-seq approaches.   
Together, such studies would improve mechanistic understanding and provide insights into 








Cell culture and Transfections 
U2OS cell lines and Fucci- U2OS cells were used in this study. The two cell lines were 
grown in Dulbecco's Modified Eagle Medium (DMEM, Hyclone) with 10% Fetal Bovine Serum 
(FBS) and 3% GlutaMAX-100X (Gibco). The cells were cultured at 5% CO2,37C and 95% 
humidified incubator.  
Plasmids 
In this study two plasmids were used to generate stable cell lines: Fucci-S-G2-M-Green 
plasmid (AM-V9016, Amalgaam)[157] obtained from Dr. Jac Nickoloff (Colorado State 
University).  For transient transfection, TRAS1-EN-TRF1 plasmid obtained from Dr. Haruhiko 
Fujiwara (University of Tokyo), TRF1 plasmid constructed from TRAS1-EN-TRF1 plasmid, and 
mutated Cas9 pSpCas9m(BB)-2A-Puro (PX462) V2.0  a gift from Feng Zhang (Addgene plasmid 
#62987 ; http://n2t.net/addgene:62987 ; RRID:Addgene_62987) and  obtained from Dr. Claudia 
Wiese (Colorado State University) were used.  
Transfections 
Stable Transfection to generate FUCCI-U2OS: U2OS expressing FUCCI-Germinin (Green 
for S-G2 and M-phase) and U2OS expressing Fucci-G1-Orange were established by transfecting 
cells with 0.5 ug of Kan-Fucci-Green (S-G2-M) plasmid. Plasmid were delivered 
using Lipofectamine 3000 ( Invitrogen) following the manufacture’s instruction. Eight hours 
following transfection, Opti-MEM media was replaced with fresh DMEM media. A week later, 
cells were trypsinized and each individual cell was seeded in 96-well plate. A positive single clone 
was identified, using the fluorescence Microscope, and expanded in presence of 800 μg/ml G-418 
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sulfate (GoldBio). After reaching 90% confluency, cells were splited into 24 well plate, 10 days 
later into 12 well plate, a week after into 6 well plate. Then, the cells were transferred into T-25 
flask and finally into a T-75 flask after 6 days. The DMEM media containing 800 μg/ml G-418 
sulfate was changed every 2 days.  
Transient transfections: Fucci-U2OS transiently expressing TRAS1-EN-TRF1 or TRF1:  
U2OS cells stably expressing FUCCI G2-Green were transfected with TRAS1-EN-TRF1 
or TRF1 using Lipofectamine 2000 (Invitrogen) following the manufacture’s instruction. Eight 
hours following transfection, Opti-MEM media was replaced with fresh DMEM media. Then, cells 
were fixed 48 h post transfection. 
Gamma Irradiation  
U2OS cells were seeded in 4 well chamber slides (Nunc Lab-Tek II 154526) at a density 
of 50,000 cell/ well. In a Mark I irradiator at Colorado State University, cells were rotated and 
exposed to 137Cs γ-rays at a dose of 2Gy. Cells then were placed back in CO2 incubator for Four 
hours preceding fixation. 
Single Stranded telomeric DNA fluorescence in-situ hybridization ssTelo-FISH and RNA 
fluorescence in-situ hybridization RNA FISH 
For combined Telomeric C rich strand detection and flag staining, U2OS expressing Fucci-
S-G2-M-Green cells were grown on 4 well chamber slides (MilliCell EZ). 48 hours following 
transfection, slides were washed with Cytoskeleton (CSK) buffer (100 mM NaCl, 1 mM EGTA, 
10 mM PIPES pH 6.8, 3 mM MgCl2, 300 mM sucrose) containing 200mM Vanadyl for 30 second. 
Cells were then fixed in freshly prepared 3% Paraformaldehyde in 10X PBS for 12 minutes at 
room temperature. Next cells were permeabilized with 0.5% Triton X-100 in CSK containing 200 
mM Vanadyl for 7 minutes at room temperature. Following permeabilization, cells were washed 
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with 70% Ethanol and dehydrated in a graded series of alcohol (85%,95% and 100% Ethanol). For 
C -rich strand (CCCTAA) detection, 0.5uM (TelG-Cy3, Bio-Synthesis) Peptide Nucleic Acid 
(PNA-GGGATT) telomere probe 0.5uM (TelC-Alexa 488, Bio-Synthesis) or (TelC- Alexa 647, 
Bio PNA 1013) Peptide Nucleic Acid (PNA-CCCTAA) telomere probe was added to the 
hybridization buffer for TERRA (UUAGGG) detection in 50% (vol/vol) formamide, 2X(vol/vol) 
Saline Sodium Citrate (SSC) hybridization buffer and 200mM Vanadyl) hybridization buffer was 
denaturated at 85oC for 10 min and cooled on ice. 200 ul hybridization buffer was added to each 
slide and slides then were placed in humidified chamber and incubated at 37oC for 6 hours. Slides 
then were washed in twice in 50% formamide in 2X SSC (2.5 minutes 42oC), twice in 4X SSC 
(2.5 minutes 42oC) and once in 2X SSC + 0.1% NP-40 (2.5 minutes 42oC). 
Pre-hybridization Rnase A and Rnase H treatment 
To remove TERRA molecules, fixed and permeabilized U2OS and U2OS expressing 
Fucci-S-G2-M-Green cells were treated with (1mg/ ml Rnase A and 15 Unit Rnase H) in 1X Rnase 
H buffer at 37oC for one hour.   
Immunofluorescence staining 
Blocking nonspecific immunoglobulin binding was carried out, following FISH, with 10% 
Goat Normal Serum (GNS) for 30 min in humidified chamber at room temperature. Following 
blocking, slides were incubated with primary antibody in 5% GNS overnight at 4C. slides were 
washed 3 times with 1XPBS at room temperature.  protein signals were visualized by incubating 
slides with fluorophore-conjugated secondary antibody for 40 min in humidified chamber   at room 
temperature and washed again 3 times in 1XPBS. Lastly, slides were mounted and counterstained 
with prolong gold antifade reagent with DAPI (Invitrogen). Primary antibodies and concentrations 
used in this study: Mouse Anti-Flag (Sigma M2 F1804, 1:2000), Rabbit Anti-Human FLAG 
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(1:300), Mouse Anti-Human TRF2 (Santa Cruz B-5, 1:200) and Mouse Anti-Human Mitosin (BD 
Biosciences 610768, 1:500). Secondary antibodies and concentrations used in this study: Alexa-
647 Goat anti-Mouse (ThermoFisher A21236, 1:750), Alexa-594 Goat anti-Mouse (ThermoFisher 
A11005, 1:750), Alexa-488 Goat anti-Rabbit (ThermoFisher A11008, 1:750) and Alexa-488 Goat 
anti-Mouse (ThermoFisher A11005, 1:750). For EdU detection, the click-iT EdU Alexa Flour 555 
was used as described by the manufacture. 
Cell cycle analysis  
The detection of cells in S phase was achieved through the incorporation of the thymidine 
analog 5-Ethynyl-2´-deoxyuridine (EdU) into DNA. Thirty min before fixation, 10uM EdU (Click-
iT, Invitrogen) was added into the culture at 37C.  Cells were considered to be in G2 when it is 
positive to FUCCI or when it is positive to FUCCI and EDU. Cell was considered to be in S phase 
cells were identified when they showed only positive stain for EdU. Finally, cells were considered 
to be in G1 when they were negative for both FUCCI and EdU.  
To evaluate the enrichment of transfected U2OS cells in G1, G2 and S phase; U2OS cells 
labeled with EdU represent S phase. Likewise, any transfected cell negative for green FUCCI and 
EdU was considered cell in G1 phase. The colocalization between FLAG and DAPI (G1 cells), 
FLAG and EdU, (S cells), and FLAG and Geminin-GFP (G2 cells), represented transfected cells 
in each phase of the cell cycle analyzed.  
Data analysis 
Telomeric RNA FISH (TERRA) analysis following IR treatment: TERRA foci number 
was counted in treated and control groups using Metamorph 7.7. The student t test was performed 
to calculate the statistical significance of number of TERRA foci between treated and control 
groups. Statistical analysis was performed with Microsoft Office Excel, n=50. 
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ENT-TRF1 and TRF1 transfection analysis: For (FLAG-DAPI) immunostaining analysis, 
cells were considered to be positively transfected when they had >20 FLAG foci. One-way 
ANOVA and Holm-Sidak test (multiple comparison test of means with 95% confidence interval), 
using the statistical software GraphPad Prism 8.0  
Immunofluorescence plus Telomeric DNA FISH and immunofluorescence plus telomeric 
RNA FISH: For (FLAG - γ-H2AX- C-strand) and (TRF2-TERRA, FLAG-TERRA, FLAG-TRF2 
-TERRA) immunostaing analysis, the number of multiple colocalization events were counted from 
the sum of 21 Z-stacks. Quantitative analysis was performed using imageJ and Cell Profiler. One-
way ANOVA was used to evaluate Statistical analysis using the statistical software GraphPad 
Prism 8.0  
Native telomeric C-Strand FISH analysis following ENT-TRF1 transfection, with and 
without RNAse treatment: C-strand foci number were counted in cellular objects using Cell 
Profiler image analysis software 3.1.5. using designed segmentation-based pipeline [178]. Our 
pipeline designed to create mask around nuclei positively transfected with FLAG and identify and 
quantify the C-strand in the same nuclear region.  One-way ANOVA and Holm-Sidak test 
(multiple comparison test of means with 95% confidence interval), using the statistical software 
GraphPad Prism 8.0  
Microscopy and Quantitative Analysis 
Images were captured blindly using 63X/1.4 N.A objective in a Zeiss Axio Imager .Z2 epi-
fluorescent microscope using Zen Blue software. Image for colocalizations were captured in 0.2 
intervals in a total of 21 z-stacks in combinations of 4 colors at the time. Quantitative analysis was 
performed using Fiji (ImageJ2) and Cell Profiler using customized pipeline for reconstructions in 
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